PriceTargets.com logo

Bio-Path - BPTH Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $40.00
  • Forecasted Upside: 1,769.16%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.14 As of 05/17/2024 01:00 AM ET
▼ -0.2 (-8.55%)

This chart shows the closing price for BPTH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bio-Path Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BPTH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BPTH

Analyst Price Target is $40.00
▲ +1,769.16% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Bio-Path in the last 3 months. The average price target is $40.00, with a high forecast of $40.00 and a low forecast of $40.00. The average price target represents a 1,769.16% upside from the last price of $2.14.

This chart shows the closing price for BPTH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Bio-Path. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/25/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/18/2024Roth MkmReiterated RatingBuy ➝ Buy$40.00Low
3/27/2024Roth MkmBoost TargetBuy ➝ Buy$12.00 ➝ $40.00Low
3/17/2023Roth CapitalReiterated RatingBuyLow
5/18/2022HC WainwrightLower TargetBuy$240.00 ➝ $180.00Low
11/15/2021HC WainwrightReiterated RatingBuy$240.00Low
4/13/2021HC WainwrightReiterated RatingBuy$240.00High
4/6/2021HC WainwrightReiterated RatingPositive ➝ Buy$200.00 ➝ $240.00Low
3/11/2021Roth CapitalInitiated CoverageBuy$260.00High
11/16/2020HC WainwrightLower TargetBuy$240.00 ➝ $200.00Medium
8/17/2020HC WainwrightReiterated RatingBuy$360.00 ➝ $240.00Low
5/18/2020HC WainwrightReiterated RatingBuy$500.00 ➝ $360.00High
1/9/2020HC WainwrightReiterated RatingBuy$500.00Low
12/2/2019HC WainwrightReiterated RatingBuy$560.00 ➝ $500.00Medium
11/18/2019HC WainwrightReiterated RatingBuy$560.00Medium
8/16/2019HC WainwrightReiterated RatingBuy$560.00Medium
7/16/2019HC WainwrightInitiated CoverageBuy$560.00High
(Data available from 5/19/2019 forward)

News Sentiment Rating

0.14 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 2 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 1 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2024

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Bio-Path logo
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.
Read More

Today's Range

Now: $2.14
Low: $2.00
High: $2.31

50 Day Range

MA: $3.57
Low: $2.14
High: $5.61

52 Week Range

Now: $2.14
Low: $2.00
High: $44.80

Volume

62,764 shs

Average Volume

269,184 shs

Market Capitalization

$1.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Bio-Path?

The following Wall Street sell-side analysts have issued research reports on Bio-Path in the last twelve months: Roth Mkm, and StockNews.com.
View the latest analyst ratings for BPTH.

What is the current price target for Bio-Path?

1 Wall Street analysts have set twelve-month price targets for Bio-Path in the last year. Their average twelve-month price target is $40.00, suggesting a possible upside of 1,769.2%. Roth Mkm has the highest price target set, predicting BPTH will reach $40.00 in the next twelve months. Roth Mkm has the lowest price target set, forecasting a price of $40.00 for Bio-Path in the next year.
View the latest price targets for BPTH.

What is the current consensus analyst rating for Bio-Path?

Bio-Path currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BPTH will outperform the market and that investors should add to their positions of Bio-Path.
View the latest ratings for BPTH.

What other companies compete with Bio-Path?

Other companies that are similar to Bio-Path include PainReform, 180 Life Sciences, Qualigen Therapeutics, Allarity Therapeutics and InMed Pharmaceuticals. Learn More about companies similar to Bio-Path.

How do I contact Bio-Path's investor relations team?

Bio-Path's physical mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The company's listed phone number is (832) 742-1357 and its investor relations email address is [email protected]. The official website for Bio-Path is www.biopathholdings.com. Learn More about contacing Bio-Path investor relations.